Akebia Therapeutics, Inc. (AKBA) Social Stream
AKEBIA THERAPEUTICS INC (AKBA) Price Targets From Analysts
Use the tables below to see what analysts covering AKEBIA THERAPEUTICS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-05 | 4 | $8 | $2.75 | $5.937 | $0.923 | 543.23% |
| 2022-01-28 | 2 | $10 | $6 | $8 | $0.923 | 766.74% |
| 2022-03-02 | 3 | $10 | $6 | $8 | $0.923 | 766.74% |
| 2022-03-08 | 4 | $10 | $6 | $8 | $0.923 | 766.74% |
| 2022-03-31 | 7 | $2 | $2 | $2 | $0.923 | 116.68% |
| 2022-05-10 | 7 | $2 | $1 | $1.75 | $0.923 | 89.6% |
| 2022-05-16 | 6 | $2 | $1.25 | $1.75 | $0.923 | 89.6% |
| 2022-06-06 | 7 | $2 | $1 | $1.562 | $0.923 | 69.23% |
| 2023-03-10 | 2 | $2 | $1.25 | $1.625 | $0.923 | 76.06% |
| 2023-04-26 | 2 | $2 | $2 | $2 | $0.923 | 116.68% |
| 2023-05-26 | 3 | $2 | $2 | $2 | $0.923 | 116.68% |
| 2023-07-24 | 3 | $4 | $2 | $3 | $0.923 | 225.03% |
| 2023-08-25 | 3 | $4 | $2 | $3 | $0.923 | 225.03% |
| 2023-11-09 | 3 | $4 | $3.75 | $3.875 | $0.923 | 319.83% |
The Trend in the Analyst Price Target
Over the past 33 months, AKBA's average price target has gone down $3.12.
AKBA reports an average of 165.44% for its upside potential over the past 35 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-10 | 2 | 2 | 1.25 | 1.625 | 0.799 | 103.38% |
| 2023-05-31 | 3 | 4 | 2.00 | 3.000 | 1.040 | 188.46% |
| 2023-08-25 | 3 | 4 | 2.00 | 3.000 | 1.150 | 160.87% |
| 2023-08-28 | 3 | 4 | 3.75 | 3.875 | 1.380 | 180.8% |
| 2023-11-09 | 3 | 4 | 3.75 | 3.875 | 0.910 | 325.82% |
AKBA Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.67 | 2 | 0 | 1 | 0 | 0 | 3 |
The Trend in the Broker Recommendations
AKBA's average broker recommendation rating improved by 1.62 over the prior 17 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, AKEBIA THERAPEUTICS INC's average analyst price target is greater than 37.83% of them.
- AKEBIA THERAPEUTICS INC's number of analysts covering the stock is greater than 242.33% of all US stocks.
- AKEBIA THERAPEUTICS INC's variance in analysts' estimates is lower than -317.68% of Pharmaceutical Products stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, AKEBIA THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is greater than 701.92% of them.
Stocks similar to AKEBIA THERAPEUTICS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are EGRX, CPRX, and LXRX.
View All Top Stocks by Price Target
Is AKBA a Buy, Hold or Sell? See the POWR Ratings now!